Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?. (3rd April 2021)

• Record Type: Journal Article
• Authors: Shi, Yan; Guo, Minna; Yang, Wenjing; Liu, Shijiang; Zhu, Bin; Yang, Ling; Yang, Chun; Liu, Cunming
• Is Part Of: Expert review of vaccines. Volume 20:Number 4(2021)
• Page Start: 375
• Page End: 383
• Publication Date: 2021-04-03
• Subjects: SARS-cov-2 -- neurodegenerative diseases -- vaccine -- covid-19 -- elderly; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2021.1911653
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Introduction: Coronavirus Disease 2019 (COVID-19) poses a substantial threat to the lives of the elderly, especially those with neurodegenerative diseases, and vaccination against viral infections is recognized as an effective measure to reduce mortality. However, elderly patients with neurodegenerative diseases often suffer from abnormal immune function and take multiple medications, which may complicate the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. Currently, there is no expert consensus on whether SARS-CoV-2 vaccines are suitable for patients with neurodegenerative diseases. Areas covered: We searched Pubmed to conduct a systematic review of published studies, case reports, reviews, meta-analyses, and expert guidelines on the impact of SARS-CoV-2 on neurodegenerative diseases and the latest developments in COVID-19 vaccines. We also summarized the interaction between vaccines and age-related neurodegenerative diseases. The compatibility of future SARS-CoV-2 vaccines with neurodegenerative diseases is discussed. Expert opinion: Vaccines enable the body to produce immunity by activating the body's immune response. The pathogenesis and treatment of neurodegenerative diseases is complex, and these diseases often involve abnormal immune function, which can substantially affect the safety and effectiveness of vaccines. In short, this article provides recommendations for the use of vaccine candidates in patients with neurodegenerative diseases.